Losmapimod (Standard)
Losmapimod (GSK-AHAB; GW856553X) (Standard) is the analytical standard of Losmapimod (HY-10402). This product is intended for research and analytical applications. Losmapimod (GSK-AHAB; GW856553X) is an orally active p38α/β MAPK inhibitor, with pKi values of 8.1 and 7.6 for p38α and p38β, respectively. Losmapimod reduces DUX4 expression, thus exerting efficacy in facioscapulohumeral muscular dystrophy. By inhibiting MAPK/NF-κB, Losmapimod reduces apoptosis of epileptiform hippocampal neurons, and exhibits anti-allodynia and anti-hyperalgesic activities. Losmapimod blocks the entry and fusion of Lassa fever virus (LASV). Losmapimod overcomes tyrosine kinase inhibitor resistance in non-small cell lung cancer (NSCLC). Losmapimod inhibits myocardial senescence and inflammation, and possesses cardioprotective activity against cardiotoxicity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 585543-15-3
- 分子式: C22H26FN3O2
- 分子量:383.46
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Product Information
-
化学情報
- 純度とドキュメンテーション
-
Help & FAQs
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
化学情報
-
CAS 番号 585543-15-3
-
分子量 383.46
-
分子式 C22H26FN3O2
-
SMILES
CC1=C(C2=NC=C(C(NCC(C)(C)C)=O)C=C2)C=C(C(NC3CC3)=O)C=C1F
-
別名
GSK-AHAB (Standard); GW856553X (Standard); SB856553 (Standard)
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1].
Tawil R, et al. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2024 May;23(5):477-486.
[Content Brief]
[2]. Zhang X, et al. Identification of a clinical compound losmapimod that blocks Lassa virus entry. Antiviral research. 2019 Jul;167:68-77. [Content Brief]
[3]. Dabour MS, et al. Losmapimod ameliorates doxorubicin-induced cardiotoxicity through attenuating senescence and inflammatory pathways. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2024 Oct;179:117288. [Content Brief]
[4]. Yeung YT, et al. Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization. EBioMedicine. 2018 Feb;28:51-61. [Content Brief]
[5]. Li M, et al. Losmapimod Protected Epileptic Rats From Hippocampal Neuron Damage Through Inhibition of the MAPK Pathway. Frontiers in pharmacology. 2019;10:625. [Content Brief]
[6].
Soued M, et al. Antinociceptive properties of losmapimod in two acute pain models in rats: behavioural analysis, immunohistochemistry, dose response, and comparison with usual analgesic drugs. BJA Open. 2022 Aug 17;3:100029.
[Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Powered by Bioz